Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference.
The company's president and chief executive officer, René Russo, Pharm.D., will engage in a fireside chat on Monday, March 3, 2025, at 9:50 am EST.
Interested parties can access a live webcast of the presentation through the 'Events & Presentations' section of Xilio's investor relations website at ir.xiliotx.com. The webcast recording will remain available on the website for 30 days after the presentation.
Xilio Therapeutics (Nasdaq: XLO), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di terapie immuno-oncologiche attivate dai tumori, ha annunciato la sua prossima partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen.
Il presidente e amministratore delegato dell'azienda, René Russo, Pharm.D., parteciperà a una chiacchierata informale lunedì 3 marzo 2025, alle 9:50 EST.
Le parti interessate possono accedere a una trasmissione in diretta della presentazione tramite la sezione 'Eventi e Presentazioni' del sito web delle relazioni con gli investitori di Xilio all'indirizzo ir.xiliotx.com. La registrazione della trasmissione rimarrà disponibile sul sito per 30 giorni dopo la presentazione.
Xilio Therapeutics (Nasdaq: XLO), una empresa de biotecnología en etapa clínica centrada en el desarrollo de terapias de inmuno-oncología activadas por tumores, ha anunciado su próxima participación en la 45ª Conferencia Anual de Salud de TD Cowen.
El presidente y director ejecutivo de la empresa, René Russo, Pharm.D., participará en una charla informal el lunes 3 de marzo de 2025, a las 9:50 am EST.
Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección 'Eventos y Presentaciones' del sitio web de relaciones con inversores de Xilio en ir.xiliotx.com. La grabación de la transmisión estará disponible en el sitio durante 30 días después de la presentación.
Xilio Therapeutics (Nasdaq: XLO), 종양 활성화 면역 종양학 치료제를 개발하는 임상 단계 생명공학 회사가 TD Cowen 제45회 연례 건강 관리 회의에 참여할 예정이라고 발표했습니다.
회사의 회장 겸 CEO인 René Russo, Pharm.D.는 2025년 3월 3일 월요일 오전 9시 50분 EST에 화상 대화에 참여할 것입니다.
관심 있는 당사자는 Xilio의 투자자 관계 웹사이트 ir.xiliotx.com의 '이벤트 및 발표' 섹션을 통해 발표의 생중계를 시청할 수 있습니다. 생중계 녹화는 발표 후 30일 동안 웹사이트에서 제공됩니다.
Xilio Therapeutics (Nasdaq: XLO), une entreprise de biotechnologie en phase clinique axée sur le développement de thérapies d'immuno-oncologie activées par les tumeurs, a annoncé sa prochaine participation à la 45e Conférence Annuelle sur la Santé de TD Cowen.
Le président et directeur général de l'entreprise, René Russo, Pharm.D., participera à une discussion informelle le lundi 3 mars 2025, à 9h50 EST.
Les parties intéressées peuvent accéder à une diffusion en direct de la présentation via la section 'Événements et Présentations' du site web des relations avec les investisseurs de Xilio à l'adresse ir.xiliotx.com. L'enregistrement de la diffusion sera disponible sur le site pendant 30 jours après la présentation.
Xilio Therapeutics (Nasdaq: XLO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von tumoraktivierten Immunonkologie-Therapien konzentriert, hat seine bevorstehende Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt.
Der Präsident und CEO des Unternehmens, René Russo, Pharm.D., wird am Montag, den 3. März 2025, um 9:50 Uhr EST, an einem informellen Gespräch teilnehmen.
Interessierte Parteien können über den Bereich 'Veranstaltungen & Präsentationen' auf der Investor-Relations-Website von Xilio unter ir.xiliotx.com auf einen Live-Stream der Präsentation zugreifen. Die Aufzeichnung des Streams wird 30 Tage nach der Präsentation auf der Website verfügbar sein.
- None.
- None.
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:50 am EST.
A live webcast can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/. A replay of the webcast will be archived on the website for 30 days following the presentation.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Investor and Media Contact
Scott Young
Vice President, Investor Relations and Corporate Communications
investors@xiliotx.com
FAQ
When is Xilio Therapeutics (XLO) presenting at the TD Cowen Health Care Conference 2025?
How can investors watch Xilio Therapeutics' (XLO) TD Cowen conference presentation?
How long will Xilio Therapeutics' (XLO) TD Cowen conference presentation be available for replay?
What type of therapies is Xilio Therapeutics (XLO) developing?
